Emibetuzumab, previously known as LY2875358, represents a unique therapeutic method in oncology, specifically targeting the MET tyrosine protein. This recombinant protein functions by specifically binding to the HGF https://gorillasocialwork.com/story27595638/emibetuzumab-a-deep-analysis-into-the-ly2875358-anti-met-immunoglobulin